(R) -Fasiglifam

(R) -Fasiglifam is the isomer of Fasiglifam (HY-10480), and can be used as an experimental control. Fasiglifam (TAK-875) is a potent, selective and orally bioavailable GPR40 agonist with EC50 of 72 nM.

Product Specifications

CAS Number

[1234474-57-7]

Product Name Alternative

(R) -TAK-875

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Free Fatty Acid Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/r-fasiglifam.html

Purity

98.95

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC1=C(C(C)=CC(OCCCS(C)(=O)=O)=C1)C2=CC(COC3=CC=C([C@H](CO4)CC(O)=O)C4=C3)=CC=C2

Molecular Formula

C29H32O7S

Molecular Weight

524.63

Precautions

H302, H315, H319, H335

References & Citations

[1]Nagatake T, et al. 17,18-EpETE-GPR40 axis ameliorates contact hypersensitivity by inhibiting neutrophil mobility in mice and cynomolgus macaques. J Allergy Clin Immunol. 2017 Dec 26. pii: S0091-6749 (17) 32949-4.|[2]Yoshiyuki Tsujihata, et al. TAK-875, an Orally Available GPR40/FFA1 Agonist Enhances Glucose-Dependent Insulin Secretion and Improves Both Postprandial and Fasting Hyperglycemia in Type 2 Diabetic Rats. JPET July 13, 2011|[3]Tsujihata Y, et al. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats.J Pharmacol Exp|[4]Urano Y, et al. Comparative hepatic transcriptome analyses revealed possible pathogenic mechanisms of fasiglifam (TAK-875) -induced acute liver injury in mice. Chem Biol Interact. 2018 Sep 20;296:185-197.